Hypertrophic defect unmasked by calcineurin expression in asymptomatic tropomodulin overexpressing transgenic mice

Mark A. Sussman, Sara Welch, Angela Walker, Raisa Klevitsky, Timothy Hewett, Sandra A. Witt, Thomas R. Kimball, Robert Price, Hae W. Lim, Jeffery D. Molkentin

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Objective: Dilation and hypertrophy often occur concurrently in cardiomyopathy, yet the interaction between these two functionally distinct conditions remains unknown. Methods: Combinatorial effects of hypertrophy and dilation were investigated by cross-breeding of two cardiomyopathic transgenic mouse lines which develop either hypertrophy (calcineurin- mediated) or dilation (tropomodulin-mediated). Results: Altering the intensity of signals driving hypertrophy and dilation in cross-bred litters resulted in novel disease phenotypes different from either parental line. Augmenting the calcineurin-dependent hypertrophic stimulus in tropomodulin overexpressing transgenics elevated heart:body weight ratios, increased ventricular wall thickness, and significantly accelerated mortality. These effects were evident in calcineurin cross-breeding to tropomodulin backgrounds of transgene homozygosity (severe dilation) or heterozygosity (mild dilation to asymptomatic). Molecular analyses indicated that tropomodulin and calcineurin signaling events in the first week after birth were critical for determination of disease outcome, substantiated by demonstration that temporary neonatal inhibition of tropomodulin expression prevents dilation. Conclusions: This study shows that postnatal timing of altered signaling in cardiomyopathic transgenic mouse models is a pivotal part of determining outcome. In addition, intensifying hypertrophic stimulation exacerbates dilated cardiomyopathy, supporting the concept of shared molecular signaling between hypertrophy and dilation. (C) 2000 Elsevier Science B.V.

Original languageEnglish (US)
Pages (from-to)90-101
Number of pages12
JournalCardiovascular Research
Volume46
Issue number1
DOIs
StatePublished - Apr 2000
Externally publishedYes

Fingerprint

Tropomodulin
Calcineurin
Transgenic Mice
Dilatation
Hypertrophy
Breeding
Dilated Cardiomyopathy
Transgenes
Cardiomyopathies
Body Weight
Parturition

Keywords

  • Cardiomyopathy
  • Contractile function
  • Heart failure
  • Hypertrophy
  • Signal transduction

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Hypertrophic defect unmasked by calcineurin expression in asymptomatic tropomodulin overexpressing transgenic mice. / Sussman, Mark A.; Welch, Sara; Walker, Angela; Klevitsky, Raisa; Hewett, Timothy; Witt, Sandra A.; Kimball, Thomas R.; Price, Robert; Lim, Hae W.; Molkentin, Jeffery D.

In: Cardiovascular Research, Vol. 46, No. 1, 04.2000, p. 90-101.

Research output: Contribution to journalArticle

Sussman, MA, Welch, S, Walker, A, Klevitsky, R, Hewett, T, Witt, SA, Kimball, TR, Price, R, Lim, HW & Molkentin, JD 2000, 'Hypertrophic defect unmasked by calcineurin expression in asymptomatic tropomodulin overexpressing transgenic mice', Cardiovascular Research, vol. 46, no. 1, pp. 90-101. https://doi.org/10.1016/S0008-6363(99)00422-8
Sussman, Mark A. ; Welch, Sara ; Walker, Angela ; Klevitsky, Raisa ; Hewett, Timothy ; Witt, Sandra A. ; Kimball, Thomas R. ; Price, Robert ; Lim, Hae W. ; Molkentin, Jeffery D. / Hypertrophic defect unmasked by calcineurin expression in asymptomatic tropomodulin overexpressing transgenic mice. In: Cardiovascular Research. 2000 ; Vol. 46, No. 1. pp. 90-101.
@article{d1c76728d00e4d7ea78c5c6f56664822,
title = "Hypertrophic defect unmasked by calcineurin expression in asymptomatic tropomodulin overexpressing transgenic mice",
abstract = "Objective: Dilation and hypertrophy often occur concurrently in cardiomyopathy, yet the interaction between these two functionally distinct conditions remains unknown. Methods: Combinatorial effects of hypertrophy and dilation were investigated by cross-breeding of two cardiomyopathic transgenic mouse lines which develop either hypertrophy (calcineurin- mediated) or dilation (tropomodulin-mediated). Results: Altering the intensity of signals driving hypertrophy and dilation in cross-bred litters resulted in novel disease phenotypes different from either parental line. Augmenting the calcineurin-dependent hypertrophic stimulus in tropomodulin overexpressing transgenics elevated heart:body weight ratios, increased ventricular wall thickness, and significantly accelerated mortality. These effects were evident in calcineurin cross-breeding to tropomodulin backgrounds of transgene homozygosity (severe dilation) or heterozygosity (mild dilation to asymptomatic). Molecular analyses indicated that tropomodulin and calcineurin signaling events in the first week after birth were critical for determination of disease outcome, substantiated by demonstration that temporary neonatal inhibition of tropomodulin expression prevents dilation. Conclusions: This study shows that postnatal timing of altered signaling in cardiomyopathic transgenic mouse models is a pivotal part of determining outcome. In addition, intensifying hypertrophic stimulation exacerbates dilated cardiomyopathy, supporting the concept of shared molecular signaling between hypertrophy and dilation. (C) 2000 Elsevier Science B.V.",
keywords = "Cardiomyopathy, Contractile function, Heart failure, Hypertrophy, Signal transduction",
author = "Sussman, {Mark A.} and Sara Welch and Angela Walker and Raisa Klevitsky and Timothy Hewett and Witt, {Sandra A.} and Kimball, {Thomas R.} and Robert Price and Lim, {Hae W.} and Molkentin, {Jeffery D.}",
year = "2000",
month = "4",
doi = "10.1016/S0008-6363(99)00422-8",
language = "English (US)",
volume = "46",
pages = "90--101",
journal = "Cardiovascular Research",
issn = "0008-6363",
publisher = "Oxford University Press",
number = "1",

}

TY - JOUR

T1 - Hypertrophic defect unmasked by calcineurin expression in asymptomatic tropomodulin overexpressing transgenic mice

AU - Sussman, Mark A.

AU - Welch, Sara

AU - Walker, Angela

AU - Klevitsky, Raisa

AU - Hewett, Timothy

AU - Witt, Sandra A.

AU - Kimball, Thomas R.

AU - Price, Robert

AU - Lim, Hae W.

AU - Molkentin, Jeffery D.

PY - 2000/4

Y1 - 2000/4

N2 - Objective: Dilation and hypertrophy often occur concurrently in cardiomyopathy, yet the interaction between these two functionally distinct conditions remains unknown. Methods: Combinatorial effects of hypertrophy and dilation were investigated by cross-breeding of two cardiomyopathic transgenic mouse lines which develop either hypertrophy (calcineurin- mediated) or dilation (tropomodulin-mediated). Results: Altering the intensity of signals driving hypertrophy and dilation in cross-bred litters resulted in novel disease phenotypes different from either parental line. Augmenting the calcineurin-dependent hypertrophic stimulus in tropomodulin overexpressing transgenics elevated heart:body weight ratios, increased ventricular wall thickness, and significantly accelerated mortality. These effects were evident in calcineurin cross-breeding to tropomodulin backgrounds of transgene homozygosity (severe dilation) or heterozygosity (mild dilation to asymptomatic). Molecular analyses indicated that tropomodulin and calcineurin signaling events in the first week after birth were critical for determination of disease outcome, substantiated by demonstration that temporary neonatal inhibition of tropomodulin expression prevents dilation. Conclusions: This study shows that postnatal timing of altered signaling in cardiomyopathic transgenic mouse models is a pivotal part of determining outcome. In addition, intensifying hypertrophic stimulation exacerbates dilated cardiomyopathy, supporting the concept of shared molecular signaling between hypertrophy and dilation. (C) 2000 Elsevier Science B.V.

AB - Objective: Dilation and hypertrophy often occur concurrently in cardiomyopathy, yet the interaction between these two functionally distinct conditions remains unknown. Methods: Combinatorial effects of hypertrophy and dilation were investigated by cross-breeding of two cardiomyopathic transgenic mouse lines which develop either hypertrophy (calcineurin- mediated) or dilation (tropomodulin-mediated). Results: Altering the intensity of signals driving hypertrophy and dilation in cross-bred litters resulted in novel disease phenotypes different from either parental line. Augmenting the calcineurin-dependent hypertrophic stimulus in tropomodulin overexpressing transgenics elevated heart:body weight ratios, increased ventricular wall thickness, and significantly accelerated mortality. These effects were evident in calcineurin cross-breeding to tropomodulin backgrounds of transgene homozygosity (severe dilation) or heterozygosity (mild dilation to asymptomatic). Molecular analyses indicated that tropomodulin and calcineurin signaling events in the first week after birth were critical for determination of disease outcome, substantiated by demonstration that temporary neonatal inhibition of tropomodulin expression prevents dilation. Conclusions: This study shows that postnatal timing of altered signaling in cardiomyopathic transgenic mouse models is a pivotal part of determining outcome. In addition, intensifying hypertrophic stimulation exacerbates dilated cardiomyopathy, supporting the concept of shared molecular signaling between hypertrophy and dilation. (C) 2000 Elsevier Science B.V.

KW - Cardiomyopathy

KW - Contractile function

KW - Heart failure

KW - Hypertrophy

KW - Signal transduction

UR - http://www.scopus.com/inward/record.url?scp=0034014981&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034014981&partnerID=8YFLogxK

U2 - 10.1016/S0008-6363(99)00422-8

DO - 10.1016/S0008-6363(99)00422-8

M3 - Article

C2 - 10727657

AN - SCOPUS:0034014981

VL - 46

SP - 90

EP - 101

JO - Cardiovascular Research

JF - Cardiovascular Research

SN - 0008-6363

IS - 1

ER -